FILING BY GENERAL STREET FUNDS

January 11, 2025

Date of Deposit

Form PTO-1390-MOD (REV 10-96)		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER VA/H-32622A								
	TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5									
	DESIGNATED/ELECTED O	Not Yet Assigned									
	CONCERNING A FILING UN	NDER 35 U.S.C. 371	10/ 521 104								
PCT/EF	NATIONAL APPLICATION NO. 203/07605	INTERNATIONAL FILING DATE 14 July 2003 (14.07.03)	PRIORITY DATE CLAIMED 15 July 2002 (15.07.02)								
TITLE OF INVENTION											
VACCINE AGAINST SALMONID RICKETTSIAL SEPTICAEMIA BASED ON ARTHROBACTER CELLS APPLICANT(S) FOR DO/EO/US											
	IUS ET AL.										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1. 🛭 2. 🔲 3. 🗍		ENT submission of items concertional examination procedures (3	ning a filing under 35 U.S.C. 371. 5 U.S.C. 371(f)) at any time rather								
4.	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.										
5. 🖂	 earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau). 										
	 b.										
8.	U.S.C.371(c)(3)). a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau). b. ☐ have been transmitted by the International Bureau. c. ☐ have not been made; however, the time limit for making such amendments has NOT expired. d. ☒ have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 11. to 16. below concern document(s) or information included.											
11. 🖂	An Information Disclosure Stat	tement under 37 CFR 1.97 and	1.98.								
12. 🗌	An assignment document for recand 3.31 is included.	ording. A separate cover sheet in	n compliance with 37 CFR 3.28								
	A FIRST preliminary amendme A SECOND or SUBSEQUENT pr										
14. 🔲	A substitute specification.										
15. 🗌	A change of power of attorney ar	nd/or address letter.									
16. 🖂	Other items or information: Ap	oplication Data Sheet, Unexecu one signed Dedai	ted Declaration and Postcard. ation (Kira Schnius)								

U.S. APPLICATION NO. (if kno	wn. see 37 CER 1.5	n		NATIONAL APPLICATION NO. /EP03/07605				NEY'S D H-326	OCKET N	IUMBER		
21. The following fees are submitted:									CALCULATIONS PTO USE ONLY			
a) Basic national fee								\$300		***************************************		
b) Examination fee								\$200				
c) Search fee												
TOTAL OF ABOVE CALCULATIONS =									\$	1000		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence licomputer program listing filed in an electronic medium). The fee is \$250 for each additional 50 short fraction thereof.										r f paper		
Total Sheets Extra st		ets	Number of each additional 50 or fraction thereof (round up to a whole number)				RATE					
- 100 =	/5	i0 =	110100	0	<u> </u>	+	\$	250	\$			
Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).									\$			
CLAIMS		BER F		NUMBER EXTRA		RAT	E					
Total claims	11	_	- 20 =	0		5		50	_\$	0		
Independent claims	4		- 3 =	1		5	20		_\$	200		
MULTIPLE DEPEND	ENT CLAIM	S) (if a	pplicable)		+ 9			30	\$			
TOTAL OF ABOVE CALCULATIONS =									\$			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be												
filed (Note 37 CFR 1	9, 1.27, 1.28).		·					\$	4 2 2 2		
							OTA		\$	1,200		
the earliest claimed p							nths f	+	\$			
TOTAL NATIONAL FEE =									\$	1,200		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +									•			
by an appropriate co	ver sneet (37	CFR 3	.20, 3.31).	TOTAL FI	EC EN	21.0	CED		<u>\$</u> \$	1,200		
			······	IOIALFI	ES EN	JLU:	2ED	=	Ψ.	1,200		
									Amo	unt to be: refunded	\$	
			- · · · · · · · · · · · · · · · · · · ·						_	charged	\$1,200	
a. A check in t	he amount of	\$		to cover the above fee	es is enclo	sed.						
	Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,200 to cover the above fees. A duplicate copy of this form is enclosed.											
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Novartis Corporate Int One Health F East Hanove	laza, Building	104		Attor Reg	d L. Marks ney for Ap . No. 37,88) 778-792:	s oplica 31					-	